West Pharmaceutical Servs Analyst Ratings
West Pharmaceutical Servs Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/30/2023 | 6.69% | Keybanc | $415 → $440 | Maintains | Overweight |
| 08/21/2023 | 0.63% | Keybanc | $385 → $415 | Maintains | Overweight |
| 07/28/2023 | -6.65% | Keybanc | $375 → $385 | Maintains | Overweight |
| 07/17/2023 | 1.84% | Stephens & Co. | $400 → $420 | Maintains | Overweight |
| 06/16/2023 | -1.8% | B of A Securities | $390 → $405 | Upgrades | Neutral → Buy |
| 04/11/2023 | -3.01% | Stephens & Co. | $330 → $400 | Upgrades | Equal-Weight → Overweight |
| 02/17/2023 | -9.07% | Keybanc | $315 → $375 | Maintains | Overweight |
| 12/14/2022 | -39.38% | Deutsche Bank | → $250 | Initiates Coverage On | → Hold |
| 12/02/2022 | -23.62% | Keybanc | $350 → $315 | Maintains | Overweight |
| 11/30/2022 | -39.38% | UBS | → $250 | Initiates Coverage On | → Neutral |
| 10/28/2022 | -39.38% | B of A Securities | $385 → $250 | Downgrades | Buy → Neutral |
| 10/28/2022 | -15.13% | Keybanc | $400 → $350 | Maintains | Overweight |
| 07/29/2022 | -16.35% | Stephens & Co. | $330 → $345 | Maintains | Equal-Weight |
| 04/29/2022 | -0.58% | B of A Securities | $475 → $410 | Maintains | Buy |
| 04/29/2022 | -3.01% | Keybanc | $475 → $400 | Maintains | Overweight |
| 09/15/2021 | 24.88% | B of A Securities | $450 → $515 | Maintains | Buy |
| 07/30/2021 | -3.01% | Stephens & Co. | $360 → $400 | Maintains | Equal-Weight |
| 07/30/2021 | 15.18% | Keybanc | $350 → $475 | Maintains | Overweight |
| 04/30/2021 | -17.56% | Stephens & Co. | $315 → $340 | Maintains | Equal-Weight |
| 02/19/2021 | -23.62% | Stephens & Co. | $300 → $315 | Maintains | Equal-Weight |
| 11/10/2020 | -15.13% | Keybanc | → $350 | Initiates Coverage On | → Overweight |
| 10/14/2020 | -27.26% | Stephens & Co. | → $300 | Initiates Coverage On | → Equal-Weight |
| 04/24/2020 | — | B of A Securities | Upgrades | Underperform → Neutral | |
| 12/12/2019 | — | B of A Securities | Downgrades | Neutral → Underperform | |
| 07/26/2019 | — | B of A Securities | Upgrades | Underperform → Neutral | |
| 05/01/2019 | — | Jefferies | Downgrades | Buy → Hold | |
| 04/23/2019 | — | William Blair | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 08/30/2023 | 6.69% | Keybanc | 415 美元 → 440 美元 | 維護 | 超重 |
| 08/21/2023 | 0.63% | Keybanc | 385 美元 → 415 美元 | 維護 | 超重 |
| 07/28/2023 | -6.65% | Keybanc | 375 美元 → 385 美元 | 維護 | 超重 |
| 07/17/2023 | 1.84% | Stephens & Co. | 400 美元 → 420 美元 | 維護 | 超重 |
| 06/16/2023 | -1.8% | B of A 類證券 | 390 美元 → 405 美元 | 升級 | 中性 → 買入 |
| 04/11/2023 | -3.01% | Stephens & Co. | 330 美元 → 400 美元 | 升級 | 重量相等 → 超重 |
| 02/17/2023 | -9.07% | Keybanc | 315 美元 → 375 美元 | 維護 | 超重 |
| 2022 年 12 月 14 日 | -39.38% | 德意志銀行 | → 250 美元 | 啓動覆蓋開啓 | → 按住 |
| 12/02/2022 | -23.62% | Keybanc | 350 美元 → 315 美元 | 維護 | 超重 |
| 11/30/2022 | -39.38% | 瑞銀（UBS） | → 250 美元 | 啓動覆蓋開啓 | → 中立 |
| 10/28/2022 | -39.38% | B of A 類證券 | 385 美元 → 250 美元 | 降級 | 買入 → 中性 |
| 10/28/2022 | -15.13% | Keybanc | 400 美元 → 350 美元 | 維護 | 超重 |
| 2022 年 7 月 29 日 | -16.35% | Stephens & Co. | 330 美元 → 345 美元 | 維護 | 重量相等 |
| 2022 年 4 月 29 日 | -0.58% | B of A 類證券 | 475 美元 → 410 美元 | 維護 | 購買 |
| 2022 年 4 月 29 日 | -3.01% | Keybanc | 475 美元 → 400 美元 | 維護 | 超重 |
| 2021 年 9 月 15 日 | 24.88% | B of A 類證券 | 450 美元 → 515 美元 | 維護 | 購買 |
| 07/30/2021 | -3.01% | Stephens & Co. | 360 美元 → 400 美元 | 維護 | 重量相等 |
| 07/30/2021 | 15.18% | Keybanc | 350 美元 → 475 美元 | 維護 | 超重 |
| 2021 年 4 月 30 日 | -17.56% | Stephens & Co. | 315 美元 → 340 美元 | 維護 | 重量相等 |
| 02/19/2021 | -23.62% | Stephens & Co. | 300 美元 → 315 美元 | 維護 | 重量相等 |
| 11/10/2020 | -15.13% | Keybanc | → 350 美元 | 啓動覆蓋開啓 | → 超重 |
| 2020 年 10 月 14 日 | -27.26% | Stephens & Co. | → 300 美元 | 啓動覆蓋開啓 | → 重量相等 |
| 2020 年 4 月 24 日 | — | B of A 類證券 | 升級 | 表現不佳 → 中性 | |
| 2019 年 12 月 12 日 | — | B of A 類證券 | 降級 | 中性 → 跑贏大盤 | |
| 07/26/2019 | — | B of A 類證券 | 升級 | 表現不佳 → 中性 | |
| 05/01/2019 | — | 傑富瑞 | 降級 | 買入 → 持有 | |
| 04/23/2019 | — | 威廉布萊爾 | 啓動覆蓋開啓 | → 跑贏大盤 |
What is the target price for West Pharmaceutical Servs (WST)?
West Pharmachical Servs（WST）的目標價格是多少？
The latest price target for West Pharmaceutical Servs (NYSE: WST) was reported by Keybanc on August 30, 2023. The analyst firm set a price target for $440.00 expecting WST to rise to within 12 months (a possible 6.69% upside). 12 analyst firms have reported ratings in the last year.
Keybanc於2023年8月30日公佈了西部製藥服務公司（紐約證券交易所代碼：WST）的最新目標股價。該分析公司將目標股價定爲440.00美元，預計WST將在12個月內上漲至6.69％（可能上漲6.69％）。去年有12家分析公司公佈了評級。
What is the most recent analyst rating for West Pharmaceutical Servs (WST)?
西部藥業服務公司（WST）的最新分析師評級是多少？
The latest analyst rating for West Pharmaceutical Servs (NYSE: WST) was provided by Keybanc, and West Pharmaceutical Servs maintained their overweight rating.
West Pharmaceical Servs（紐約證券交易所代碼：WST）的最新分析師評級由Keybanc提供，West Pharmaceical Servs維持其增持評級。
When is the next analyst rating going to be posted or updated for West Pharmaceutical Servs (WST)?
West Pharmaceical Servs（WST）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of West Pharmaceutical Servs, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for West Pharmaceutical Servs was filed on August 30, 2023 so you should expect the next rating to be made available sometime around August 30, 2024.
分析師在進行了廣泛的研究後得出了股票評級，包括閱讀公開財務報表、與西部製藥服務公司的高管和客戶交談以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。西部製藥服務公司的最後一次評級是在2023年8月30日提交的，因此你應該預計下一個評級將在2024年8月30日左右公佈。
Is the Analyst Rating West Pharmaceutical Servs (WST) correct?
分析師對西部製藥服務（WST）的評級是否正確？
While ratings are subjective and will change, the latest West Pharmaceutical Servs (WST) rating was a maintained with a price target of $415.00 to $440.00. The current price West Pharmaceutical Servs (WST) is trading at is $412.41, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的西部製藥服務公司（WST）評級保持不變，目標股價爲415.00美元至440.00美元。西部製藥服務公司（WST）目前的交易價格爲412.41美元，超出了分析師的預期區間。